Drug Approvals
Page 3 • 8 itemsTrack global drug approvals & regulatory decisions. Gain critical intelligence on new therapies, market access, and competitive landscapes for pharma BD.
![NMPA Approval [Drug Name]: Impact on China’s Oncology Market 2025](/uploads/articles/nmpa-approval-drugname-oncology-market-analysis-2025.webp)
NMPA Approval [Drug Name]: Impact on China’s Oncology Market 2025
The NMPA's approval of Drug Name marks a significant milestone for China's oncology market in 2025, promising enhanced treatment options for cancer patients.
PMDA SAKIGAKE Designation: Accelerating Novel Cardiovascular Drug Approvals
Explore the impact of PMDA SAKIGAKE Designation on speeding up the approval process for groundbreaking cardiovascular drugs, including CardioX.
PMDA SAKIGAKE Designation: Expediting Innovative Drug Approvals in Japan
The PMDA SAKIGAKE Designation streamlines the approval process for innovative drugs, enhancing patient access to groundbreaking treatments in Japan.
NMPA Accelerated Approval Oncology: What You Need to Know
Explore the NMPA's accelerated approval pathway for oncology, focusing on its implications for drugs like XYZ in enhancing patient access to vital cancer therapies.
NMPA Approval Oncology Drugs: Accelerated & Conditional Pathways Explained
This article delves into the NMPA's accelerated and conditional pathways for oncology drugs, highlighting their significance in expediting approvals for critical treatments.
PMDA SAKIGAKE Designation: Impact on Expedited Approvals & Rare Diseases
The PMDA SAKIGAKE Designation significantly impacts expedited drug approvals, particularly for rare diseases, improving access to treatments like XYZ drug.
Corcept Therapeutics Faces FDA Rejection of Relacorilant for Cushing's Syndrome, Investor Lawsuit Filed
Corcept Therapeutics received FDA Complete Response Letter rejecting relacorilant for Cushing's syndrome due to insufficient evidence, sparking investor lawsuit.
NMPA Accelerated Approval Orphan Drugs: Impact & Future Trends in China
This article delves into the NMPA's accelerated approval process for orphan drugs, focusing on its implications for rare disease treatments in China.